

Information for Prescribers of Prescription Drugs per Colorado House Bill 19-1131

Tecelra® (afamitresgene autoleuecel)

This notification is being provided per Colorado House Bill 19-1131 to support the requirement of providing information to Colorado prescribers when engaging in prescription drug marketing. This notice contains the Wholesale Acquisition Cost (WAC) of Adaptimmune’s prescription drug product listed in Table 1 below and the names of generic prescription drug product(s) in the same therapeutic class, as available, listed in Table 2.

The WAC listed is representative of the WAC as published by Wolters Kluwer Medi-Span and is based on data submitted to the compendia as of the date indicated at the bottom of this notification. WACs are typically representative of the prices paid by wholesalers and/or direct purchasers. The actual prices paid by consumers may differ significantly. The below WAC does not necessarily reflect price per dosage, price per course of treatment, or the cost effectiveness of the prescription drug product listed.

This notification and the pricing contained herein do not imply that the prescription drug product listed is interchangeable with any other prescription drug product or have the same efficacy or safety as any other prescription drug product. Tecelra’s FDA-approved label and indication should be referenced for further information.

Table 1

NDC	Product Description	Package Size	WAC
83205-0001-02	2.68 to 10 x 10 ⁹ MAGE-A4 TCR-positive T-cells in infusion bag(s) for intravenous infusion	One or more 250 mL infusion bag(s)	\$727,000

Table 2

Generic Prescription Drugs
None

Compendia Data Source: Wolters Kluwer Medi-Span
Date as of: August 8, 2024